DexCom

230 articles with DexCom

• Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time

  10/9/2019

  DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2019 financial results after market close on Wednesday, November 6, 2019

• Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM

  10/8/2019

  First and only single-use, professional CGM system with blinded or unblinded mode

• Dexcom Appoints Bridgette Heller to Board of Directors

  9/17/2019

  Ms. Heller brings more than 35 years of experience at Fortune 100 companies, including several key leadership positions with global oversight.

• Dexcom Promotes Quentin Blackford to Chief Operating Officer

  9/17/2019

  DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Quentin Blackford to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer.

• Dexcom Announces Upcoming Conference Presentations - Aug. 2, 2019

  8/2/2019

  DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conferences:

• Dexcom Reports Second Quarter 2019 Financial Results

  7/31/2019

  DexCom, Inc. reported its financial results as of and for the quarter ended June 30, 2019.

• Dexcom Schedules Second Quarter 2019 Earnings Release and Conference Call for July 31, 2019 at 4:30 p.m. Eastern Time

  7/2/2019

  To listen to the conference call, please dial (800) 446-1671 (US/Canada) or (847) 413-3362 (International) and use the confirmation number "47626297" approximately five minutes prior to the start time.

• Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data

  6/6/2019

  DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. T

• Dexcom Announces Upcoming Conference Presentation - May 22, 2019

  5/22/2019

  DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference

• Dexcom Reports First Quarter 2019 Financial Results

  5/1/2019

  DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2019.

• Dexcom Schedules First Quarter 2019 Earnings Release and Conference Call for May 1, 2019 at 4:30 p.m. Eastern Time

  4/3/2019

  DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2019 financial results after market close on Wednesday, May 1, 2019.

• Dexcom Announces Upcoming Conference Presentation - February 25, 2019

  2/25/2019

  DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference

• Dexcom G6® CGM System Receives Health Canada Approval

  2/22/2019

  Dexcom, Inc., a leader in continuous glucose monitoring, announced that the company has received Health Canada approval for its next generation Dexcom G6 CGM System for people with diabetes ages two years and up.

• Dexcom Reports Fourth Quarter and Fiscal Year 2018 Financial Results

  2/21/2019

  The Company also Announces Expansion and Reorganization of its Customer Support Functions

• Dexcom Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 21, 2019 at 4:30 p.m. Eastern Time

  1/24/2019

  DexCom (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Thursday, February 21, 2019.

• Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook

  1/7/2019

  For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.

• Dexcom Announces Upcoming January 2019 Conference Presentation

  12/18/2018

  DexCom, Inc. today announced that management will present an update on Dexcom at the following upcoming investor conference

• Dexcom Donates $25,000 to Beyond Type 1

  12/11/2018

  Social media campaign #NoMoreFingerpricks raises funds and awareness for diabetes research

• DexCom Prices Offering of $750.0 Million of 0.75% Convertible Senior Notes

  11/28/2018

  DexCom, Inc. announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended

• DexCom Announces Proposed Offering of $750 Million of Convertible Senior Notes

  11/26/2018

  DexCom, Inc. announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).